Health Care·Biotechnology·$4.5B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.56 | N/A | -72.06% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-0.56 | N/A | -72.06% |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Management expressed caution regarding the current financial performance. They emphasized their commitment to advancing their pipeline despite the losses.
Management did not provide specific guidance for future performance.
The company is focusing on its ongoing clinical trials and product development.
Amicus Therapeutics reported a larger-than-expected loss per share, which contributed to a 4.1% decline in stock price. The lack of revenue figures and forward guidance may raise concerns among investors about the company's financial health and future performance. The focus on clinical trials suggests that the company is prioritizing long-term growth over short-term financial results.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
AMERICAN INTL GROUP
May 6, 2019